Emergence of Quinolone Resistance Among Viridans Group Streptococci Isolated from the Oropharynx of Neutropenic Peripheral Blood Stem Cell Transplant Patients Receiving Quinolone Antimicrobial Prophylaxis

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2005 Dec 7

PMID 16331335

Citations 13

Authors

R M Prabhu

K E Piper

M R Litzow

J M Steckelberg

R Patel

Affiliations

Soon will be listed here.

Abstract

In neutropenic patients receiving quinolone prophylaxis, bacteremia with viridans group streptococci resistant to quinolones is a known complication. The frequency of occurrence of quinolone-resistant organisms colonizing the oropharynx during antibacterial prophylaxis with a quinolone is not well defined. In 48 patients undergoing hematopoietic stem cell transplantation, the prevalence of quinolone resistance in viridans group streptococci colonizing the oropharynx before and during antibacterial prophylaxis with gatifloxacin or moxifloxacin (most with concomitant penicillin) was determined. For quinolone-resistant isolates, mutations in the genes gyrA and parC, which confer resistance to quinolones, were analyzed. Seventy-four isolates before and 27 isolates during quinolone use were recovered from patients' oropharynxes. The numbers of susceptible isolates recovered before versus during quinolone use were as follows: 52 (70%) versus three (11%) for ciprofloxacin, 66 (89%) versus eight (30%) for levofloxacin, 66 (89%) versus ten (37%) for gatifloxacin, and 67 (91%) versus 11 (41%) for moxifloxacin (p<0.0001). Mutations in gyrA and/or parC were detected in quinolone-resistant isolates. Quinolone-resistant viridans group streptococci are frequently found in the oropharynx of neutropenic patients after a brief (median, 8 days) exposure to gatifloxacin or moxifloxacin.

Citing Articles

Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients.

Gottesdiener L, Satlin M Transpl Infect Dis. 2023; 25 Suppl 1:e14169.

PMID: 37864309 PMC: 10844985. DOI: 10.1111/tid.14169.

Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients.

Santos C, Rhee Y, Czapka M, Kazi A, Proia L J Clin Med. 2020; 9(3).

PMID: 32245201 PMC: 7141503. DOI: 10.3390/jcm9030865.

Fitness Landscape of the Immune Compromised Favors the Emergence of Antibiotic Resistance.

Margolis E, Rosch J ACS Infect Dis. 2018; 4(9):1275-1277.

PMID: 30070470 PMC: 6358436. DOI: 10.1021/acsinfecdis.8b00158.

Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia.

Ganti B, Marini B, Nagel J, Bixby D, Perissinotti A Support Care Cancer. 2016; 25(2):541-547.

PMID: 27738797 DOI: 10.1007/s00520-016-3436-3.

Involvement of NADH Oxidase in Competition and Endocarditis Virulence in Streptococcus sanguinis.

Ge X, Yu Y, Zhang M, Chen L, Chen W, Elrami F Infect Immun. 2016; 84(5):1470-1477.

PMID: 26930704 PMC: 4862721. DOI: 10.1128/IAI.01203-15.

References

Facklam R . What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev. 2002; 15(4):613-30. PMC: 126867. DOI: 10.1128/CMR.15.4.613-630.2002. View

Patrick C . Use of fluoroquinolones as prophylactic agents in patients with neutropenia. Pediatr Infect Dis J. 1997; 16(1):135-9; discussion 160-2. DOI: 10.1097/00006454-199701000-00038. View

Bochud P, Calandra T, Francioli P . Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med. 1994; 97(3):256-64. DOI: 10.1016/0002-9343(94)90009-4. View

Kaneko A, Sasaki J, Shimadzu M, Kanayama A, Saika T, Kobayashi I . Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. J Antimicrob Chemother. 2000; 45(6):771-5. DOI: 10.1093/jac/45.6.771. View

Schmitz F, Fisher A, Boos M, Mayer S, Milatovic D, Fluit A . Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis, and Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis. 2001; 20(3):219-22. DOI: 10.1007/pl00011257. View

Yuen K, Woo P, Liang R, Chiu E, Chen F, Wong S . Clinical significance of alimentary tract microbes in bone marrow transplant recipients. Diagn Microbiol Infect Dis. 1998; 30(2):75-81. DOI: 10.1016/s0732-8893(97)00213-7. View

. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for.... JAMA. 1994; 272(15):1183-9. View

Janoir C, Podglajen I, Kitzis M, Poyart C, Gutmann L . In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. J Infect Dis. 1999; 180(2):555-8. DOI: 10.1086/314888. View

Persson L, Vikerfors T, Sjoberg L, Engervall P, Tidefelt U . Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia. Scand J Infect Dis. 2001; 32(6):615-21. DOI: 10.1080/003655400459513. View

10.

Kern W, Kurrle E . Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia. Infection. 1991; 19(2):73-80. DOI: 10.1007/BF01645571. View

11.

Elting L, Bodey G, Keefe B . Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992; 14(6):1201-7. DOI: 10.1093/clinids/14.6.1201. View

12.

Timmers G, Dijstelbloem Y, Simoons-Smit A, van Winkelhoff A, Touw D, Vandenbroucke-Grauls C . Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. Bone Marrow Transplant. 2004; 33(8):847-53. DOI: 10.1038/sj.bmt.1704431. View

13.

Erickson P, Herzberg M . Emergence of antibiotic resistant Streptococcus sanguis in dental plaque of children after frequent antibiotic therapy. Pediatr Dent. 1999; 21(3):181-5. View

14.

Prentice H, Hann I, Nazareth B, Paterson P, Bhamra A, Kibbler C . Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol. 2001; 115(1):46-52. DOI: 10.1046/j.1365-2141.2001.03034.x. View

15.

Schots R, Trullemans F, Van Riet I, Kaufman L, Hafsia A, Meddeb B . The clinical impact of early gram-positive bacteremia and the use of vancomycin after allogeneic bone marrow transplantation. Transplantation. 2000; 69(7):1511-4. DOI: 10.1097/00007890-200004150-00053. View

16.

Gonzalez I, Georgiou M, Alcaide F, Balas D, Linares J, de la Campa A . Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother. 1998; 42(11):2792-8. PMC: 105945. DOI: 10.1128/AAC.42.11.2792. View

17.

Bow E, Mandell L, Louie T, Feld R, Palmer M, Zee B . Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med. 1996; 125(3):183-90. DOI: 10.7326/0003-4819-125-3-199608010-00004. View

18.

Bassetti M, Dembry L, Farrel P, Callan D, Andriole V . Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria. Diagn Microbiol Infect Dis. 2001; 41(3):143-8. DOI: 10.1016/s0732-8893(01)00298-x. View

19.

Bochud P, Eggiman P, Calandra T, van Melle G, Saghafi L, Francioli P . Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994; 18(1):25-31. DOI: 10.1093/clinids/18.1.25. View

20.

Ferrandiz M, Oteo J, Aracil B, Gomez-Garces J, de la Campa A . Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci. Antimicrob Agents Chemother. 1999; 43(10):2520-3. PMC: 89512. DOI: 10.1128/AAC.43.10.2520. View